Volume | 510,498 |
|
|||||
News | - | ||||||
Day High | 7.53 | Low High |
|||||
Day Low | 7.26 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Fulcrum Therapeutics Inc | FULC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.26 | 7.26 | 7.53 | 7.44 | 7.25 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,572 | 510,498 | $ 7.43 | $ 3,793,901 | - | 2.43 - 13.70 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:49:35 | 24 | $ 7.29 | USD |
Fulcrum Therapeutics (FULC) Options Flow Summary
Fulcrum Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
461.42M | 61.94M | - | 2.81M | -97.34M | -1.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Fulcrum Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FULC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.25 | 7.53 | 6.67 | 7.13 | 507,452 | 0.19 | 2.62% |
1 Month | 9.46 | 9.81 | 6.67 | 8.24 | 511,366 | -2.02 | -21.35% |
3 Months | 7.49 | 13.70 | 6.67 | 9.55 | 653,703 | -0.05 | -0.67% |
6 Months | 3.63 | 13.70 | 3.14 | 7.50 | 624,246 | 3.81 | 104.96% |
1 Year | 2.74 | 13.70 | 2.43 | 5.54 | 1,020,996 | 4.70 | 171.53% |
3 Years | 11.60 | 33.0975 | 2.25 | 11.38 | 1,000,339 | -4.16 | -35.86% |
5 Years | 14.50 | 33.0975 | 2.25 | 11.41 | 671,136 | -7.06 | -48.69% |
Fulcrum Therapeutics Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. |